Abstract 1927P
Background
Approximately 15% of metastatic DTC will become RR, with a substantial impact on its prognosis. Although the majority of pts with RR-DTC initially achieve disease control with TKI, most will eventually develop treatment resistance and disease progression. AL2846, a multikinase inhibitor, mediate tumor growth and angiogenesis inluding VEGFR, AxL, c-MET, may lead to improved efficacy of pts with RR-DTC treated with prior TKI.
Methods
This multi-center, open-label, phase Ib study enrolled RR-DTC pts treaed with prior TKI therapy. Eligible pts received oral 90mg or 120mg of AL2846 capsules, once daily. The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS) and safety.
Results
From 16 Feb 2023 to 31 Mar 2024, total 28 pts (90mg, n=17; 120mg, n=11) were enrolled in this study, with 27 pts (96%) remaining on treatment. 20 pts were papillary carcinoma, 8 pts were follicular carcinoma. All pts had progressed following 1 or 2 prior VEGFR-targeted therapy, about 22% patients received 2 lines of prior therapy. Among the 28 pts, 21 were efficacy evaluable, 7 have not reached the first evaluation. 2 pts achieved partial response (PR), while 19 pts had stable disease (SD) at best response, 11 pts had SD more than 16 weeks. DCR was 100% (21/21). The most common (>20%) treatment-emergent adverse events (TEAE) included AST/ALT increased, hypocalcemia, hypertension, elevated lactic dehydrogenase (LDH), hypercholesterolemia, hand-foot syndrome (HFS). TEAE ≥ grade 3 occurred in 5% of pts, only 1 patient had serious adverse event (SAE) of nephrotic syndrome. 4 pts led to dose reduction of AL2846 mainly due to HFS, proteinuria and oral mucositis. Interestingly, 1 patient achieved tumor shrinkage after dose-upregulation to 120mg during treatment, and was well tolerated.
Conclusions
AL2846 demonstrated a well-tolerated safety profile and a promising antitumor activity in previously TKI treated RR-DTC pts, which warrants further clinical evaluation.
Clinical trial identification
NCT05745363.
Editorial acknowledgement
Legal entity responsible for the study
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1919P - Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Presenter: Luigi Cerbone
Session: Poster session 18
1918P - Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience
Presenter: Manal Elgendy
Session: Poster session 18
1917P - Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma
Presenter: Vilde Haakensen
Session: Poster session 18
1916P - Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study
Presenter: LUANA CALABRO
Session: Poster session 18
1915P - Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
Presenter: Matthew Ning
Session: Poster session 18
1914P - Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Presenter: Omar Abdel-Rahman
Session: Poster session 18
1913P - Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance
Presenter: Joyce Chan
Session: Poster session 18
1912P - AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
Presenter: Samaantha Bove
Session: Poster session 18
1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France
Presenter: Laurent Greillier
Session: Poster session 18